Docosahexaenoic acid

Drug Profile

Docosahexaenoic acid

Alternative Names: SC 411

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Sancilio & Company
  • Class Antihyperlipidaemics; Docosahexaenoic acids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Sickle cell anaemia

Most Recent Events

  • 01 Feb 2017 Sancilio and Company initiates a phase II trial for Sickle cell anaemia (In children, In adolescents) in USA (PO) (NCT02973360)
  • 19 Dec 2016 Phase-III clinical trials in Sickle cell anaemia (In adolocents, In Children) in USA (PO)
  • 23 Nov 2016 Sancilio and Company plans a phase II trial for Sickle cell anaemia (In children, In adolescents) in USA (PO) (NCT02973360)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top